2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|January 20, 2005
MHRA to Reinspect Chiron Flu Vaccine Plant
Author(s)Pharmaceutical Technology Editors
MHRA to Reinspect Chiron Flu Vaccine Plant
Advertisement
On 12 January, Howard Pien, CEO of Chiron (Emeryville, CA,
Although the inspections and remediation effort "may advance towardtherestoration of the facility's license, as successive phases ofmanufacturing pass inspection by the MHRA," (in the words of a
Chiron has not responded to questions this week asking whetherinspections actually have been scheduled.
Douglas McCormick
Advertisement
Related to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Advertisement
Advertisement